分享临床研究报告的必要性：来自达菲经验的建议。
The imperative to share clinical study reports: recommendations from the Tamiflu experience.
机构信息
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
PLoS Med. 2012;9(4):e1001201. doi: 10.1371/journal.pmed.1001201. Epub 2012 Apr 10.
Abstract
Peter Doshi and colleagues describe their experience trying and failing to access clinical study reports from the manufacturer of Tamiflu and challenge industry to defend their current position of RCT data secrecy.
摘要
彼得·多希（Peter Doshi）及其同事描述了他们试图从达菲（Tamiflu）制造商处获取临床研究报告但却失败的经历，并对制药行业目前对 RCT 数据保密的立场提出质疑。
相似文献
1
The imperative to share clinical study reports: recommendations from the Tamiflu experience.分享临床研究报告的必要性：来自达菲经验的建议。
PLoS Med. 2012;9(4):e1001201. doi: 10.1371/journal.pmed.1001201. Epub 2012 Apr 10.
2
The Tamiflu saga continues: will our conduct change after the publication of the latest systematic review on benefits and harms of oseltamivir?达菲的故事仍在继续：在关于奥司他韦利弊的最新系统评价发表后，我们的行为会改变吗？
Medwave. 2014 May 20;14(4):e5953. doi: 10.5867/medwave.2014.04.5953.
3
Open clinical trial data for all? A view from regulators.公开所有临床试验数据？监管者的观点。
PLoS Med. 2012;9(4):e1001202. doi: 10.1371/journal.pmed.1001202. Epub 2012 Apr 10.
4
The Tamiflu trials.达菲试验。
BMJ. 2014 Apr 9;348:g2630. doi: 10.1136/bmj.g2630.
5
Why don't we have all the evidence on oseltamivir?为什么我们没有关于奥司他韦的所有证据？
BMJ. 2009 Dec 8;339:b5351. doi: 10.1136/bmj.b5351.
6
Questions remain over safety and effectiveness of oseltamivir.关于奥司他韦的安全性和有效性仍存在疑问。
BMJ. 2012 Jan 17;344:e467. doi: 10.1136/bmj.e467.
7
[Neuraminidase inhibitors: effects still unclear].[神经氨酸酶抑制剂：效果仍不明确]
Dtsch Med Wochenschr. 2012 Oct;137(41):2086. doi: 10.1055/s-0032-1329128. Epub 2012 Oct 2.
8
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.用于预防和治疗健康成人及儿童流感的神经氨酸酶抑制剂。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. doi: 10.1002/14651858.CD008965.pub3.
9
[How safe was oseltamivir care in the flu pandemic?].流感大流行期间奥司他韦治疗的安全性如何？
Pharm Unserer Zeit. 2011 Mar;40(2):151-4. doi: 10.1002/pauz.201100411.
10
Tamiflu: what dermatologists need to know.达菲：皮肤科医生需要了解的内容。
J Drugs Dermatol. 2010 Jan;9(1):76-8.
引用本文的文献
1
[Not Available].[无可用内容]。
CMAJ. 2024 Jul 14;196(25):E894-E896. doi: 10.1503/cmaj.231595-f.
2
Clinical trial registration and results reporting: a call for transparency, coordination, and meaningful enforcement.临床试验注册与结果报告：呼吁透明度、协调性及切实有效的执行
CMAJ. 2024 May 12;196(18):E628-E629. doi: 10.1503/cmaj.231595.
3
A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies.制药公司临床试验数据共享原则的 10 年更新：基于十年文献和政策的观点。
BMC Med. 2023 Oct 23;21(1):400. doi: 10.1186/s12916-023-03113-0.
4
Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?欧盟临床试验数据透明度：新的临床试验法规会带来变革吗？
IIC Int Rev Ind Prop Copyr Law. 2023;54(5):732-763. doi: 10.1007/s40319-023-01329-4. Epub 2023 May 4.
5
Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis.2016-2018 年欧洲药品管理局发布的临床研究报告：一项横断面分析。
BMJ Open. 2023 May 15;13(5):e068981. doi: 10.1136/bmjopen-2022-068981.
6
Conducting separate reviews of benefits and harms could improve systematic reviews and meta-analyses.分别对获益和危害进行评价，可能会提高系统评价和荟萃分析的质量。
Syst Rev. 2023 Apr 15;12(1):67. doi: 10.1186/s13643-023-02234-0.
7
An analysis of deficiencies in the ethics committee data of certain interventional trials registered with the Clinical Trials Registry-India.对在印度临床试验注册中心注册的某些干预性试验伦理委员会数据缺陷的分析。
PLOS Glob Public Health. 2022 Oct 24;2(10):e0000617. doi: 10.1371/journal.pgph.0000617. eCollection 2022.
8
Sharing individual participant data: through a systematic reviewer lens.分享个体参与者数据：从系统评价者的视角。
Trials. 2022 Feb 21;23(1):167. doi: 10.1186/s13063-021-05787-4.
9
Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information.集中全面获取临床研究数据有助于支持公正的指南制定、继续医学教育以及患者信息提供。
J Eur CME. 2021 Nov 22;10(1):1989172. doi: 10.1080/21614083.2021.1989172. eCollection 2021.
10
Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin.系统评价文献中的危害 2：评估危害的方法在加巴喷丁的系统评价中被忽视。
J Clin Epidemiol. 2022 Mar;143:212-223. doi: 10.1016/j.jclinepi.2021.10.024. Epub 2021 Nov 3.
本文引用的文献
1
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.用于预防和治疗健康成人及儿童流感的神经氨酸酶抑制剂。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. doi: 10.1002/14651858.CD008965.pub3.
2
EMA's response to articles.欧洲药品管理局对文章的回应。
BMJ. 2011 Jun 20;342:d3838. doi: 10.1136/bmj.d3838.
3
Opening up data at the European Medicines Agency.欧洲药品管理局开放数据。
BMJ. 2011 May 10;342:d2686. doi: 10.1136/bmj.d2686.
4
Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.药品标签外营销的策略和实践：告密者投诉的回顾性分析。
PLoS Med. 2011 Apr;8(4):e1000431. doi: 10.1371/journal.pmed.1000431. Epub 2011 Apr 5.
5
The inverse benefit law: how drug marketing undermines patient safety and public health.逆反效益定律：药品营销如何破坏患者安全和公共健康。
Am J Public Health. 2011 Mar;101(3):399-404. doi: 10.2105/AJPH.2010.199844. Epub 2011 Jan 13.
6
Ensuring safe and effective drugs: who can do what it takes?确保药物安全有效：谁能做到？
BMJ. 2011 Jan 11;342:c7258. doi: 10.1136/bmj.c7258.
7
Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study.医学期刊的利益冲突：行业支持的随机试验对期刊影响因子和收入的影响 - 队列研究。
PLoS Med. 2010 Oct 26;7(10):e1000354. doi: 10.1371/journal.pmed.1000354.
8
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.瑞波西汀治疗重性抑郁障碍的急性期疗效：基于已发表和未发表的安慰剂对照及选择性 5-羟色胺再摄取抑制剂对照试验的系统评价和荟萃分析。
BMJ. 2010 Oct 12;341:c4737. doi: 10.1136/bmj.c4737.
9
Rosiglitazone: what went wrong?罗格列酮：问题出在哪里？
BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848.
10
Safety and pharmacokinetics of oseltamivir at standard and high dosages.奥司他韦标准剂量和高剂量的安全性和药代动力学。
Int J Antimicrob Agents. 2010 May;35(5):461-7. doi: 10.1016/j.ijantimicag.2009.12.023. Epub 2010 Mar 1.
Zotero 插件